Company news
Axogen, Inc. (NASDAQ:AXGN) news
Every Axogen, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference
September 1, 2026
Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Te...
July 29, 2026
Axogen, Inc. Reports Second Quarter 2026 Financial Results
July 29, 2026
Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
July 15, 2026
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
April 30, 2026
Axogen, Inc. Reports First Quarter 2026 Financial Results
April 28, 2026
CVRx Announces Nomination of Michael Dale for Election to the Board of Directors
April 20, 2026
Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026
April 14, 2026
Axogen : Conference Call Presentation FY 2025
February 25, 2026
Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results
February 24, 2026
Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
February 10, 2026
Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock
January 21, 2026
Axogen Announces Proposed Public Offering of Common Stock
January 21, 2026
Axogen : J.P. Morgan 2026 Healthcare Conference
January 15, 2026
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025
January 12, 2026
Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference
December 17, 2025
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
December 3, 2025
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
November 4, 2025
Axogen, Inc. Reports Third Quarter 2025 Financial Results
October 29, 2025
Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025
October 15, 2025
Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft
August 25, 2025
Axogen, Inc. Reports Second Quarter 2025 Financial Results
August 5, 2025
Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference
July 29, 2025
Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025
July 22, 2025
Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference
May 28, 2025
Axogen Announces Chief Financial Officer Transition
May 8, 2025
Axogen, Inc. Reports 2025 First Quarter Financial Results
May 8, 2025
Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025
April 24, 2025
Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under...
March 24, 2025
Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results
February 25, 2025
Axogen, Inc. To Host Analyst & Investor Day on March 4th
February 25, 2025
Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025
February 11, 2025
Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(...
February 3, 2025
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024
January 10, 2025
Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2025
Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update
November 7, 2024
Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024
October 24, 2024
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®
September 6, 2024
Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4)
September 3, 2024
Axogen, Inc. Reports Second Quarter 2024 Financial Results
August 8, 2024
Axogen, Inc. Announces New Leadership Appointments
August 8, 2024
Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
July 23, 2024
Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)
July 1, 2024
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
June 24, 2024
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
May 28, 2024
Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
May 16, 2024
Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
May 14, 2024
Axogen, Inc Reports First Quarter 2024 Financial Results
May 2, 2024
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
April 29, 2024
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
April 16, 2024